Global Orphan Drugs Market to Reach $855.3 Billion by 2030
The global market for Orphan Drugs estimated at US$260.2 Billion in the year 2022, is projected to reach a revised size of US$855.3 Billion by 2030, growing at a CAGR of 16% over the analysis period 2022-2030. Biologics, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$548.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Biologics segment is readjusted to a revised 14.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $76.1 Billion, While China is Forecast to Grow at 15.2% CAGR
The Orphan Drugs market in the U.S. is estimated at US$76.1 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$145.5 Billion by the year 2030 trailing a CAGR of 15.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.9% and 13% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10.4% CAGR.Select Competitors (Total 18 Featured) -
- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- AstraZeneca Plc.
- Bayer AG
- Biogen Inc.
- BioMarin Pharmaceutical Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corp.
- CEL-SCI Corporation
- Concordia International Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genzyme Corp.,
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono SA
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Sanofi SA
- Shire Plc.
- Vertex Pharmaceuticals
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- A Prelude
- Recent Market Activity
- Increasing Adoption of Orphan Drugs by Manufacturers
- The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
- Major Orphan Drugs Legislations Worldwide
- Orphan Drugs Market on a Rapid Growth Trajectory
- Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU
- Incentives for Orphan Drug Designation Products in the US, EU, and Japan
- Market Challenges
- Obstacles for Conducting Orphan Drug Research
- Competition
- Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
- Important Orphan Drugs in Pipeline
- Orphan Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
- AbbVie, Inc. (USA)
- Actelion Pharmaceuticals Ltd. (Switzerland)
- Alexion Pharmaceuticals, Inc. (USA)
- Amgen, Inc. (USA)
- AstraZeneca Plc. (UK)
- Bayer AG (Germany)
- Biogen Inc. (USA)
- BioMarin Pharmaceutical Inc. (USA)
- Boehringer Ingelheim GmbH (Germany)
- Bristol-Myers Squibb Company (USA)
- Celgene Corp. (USA)
- CEL-SCI Corporation (USA)
- Concordia International Corp. (Canada)
- Eli Lilly and Company (USA)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Johnson & Johnson (USA)
- Merck & Co., Inc. (USA)
- Merck Serono International S.A. (Germany)
- Merck Serono International S.A. (Germany)
- Novartis AG (Switzerland)
- Pfizer, Inc. (USA)
- Recordati S.p.A. (Italy)
- Orphan Europe (France)
- Shire Plc. (Ireland)
- Sanofi SA (France)
- Genzyme Corp. (USA)
- Vertex Pharmaceuticals (USA)
3. MARKET TRENDS & DRIVERS
- Regulatory Incentives - A Push in the Right Direction
- Growing Unmet Medical Needs - Fulfilling the Gap
- Rising Incidence of Rare Forms of Cancer - Opportunities Galore
- Select Orphan Drugs for Cancer
- Rise in Incidence of Renal Cell Carcinoma
- Unmet Needs in AML
- Aging Population Offers Growth Potential
- Pre-Symptomatic Screening to Expand Market Base
- Asia’s Rising Awareness and Growing Population to Drive Sales
- Drug Repurposing Provides Therapies for Rare Diseases
- The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
- Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics
- Mergers and Acquisitions Drive Market Growth
- Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
- Growing Scrutiny over Skyrocketing Prices
- Orphan Drugs with High Prices: 2016
- Medical Advancements Foster Growth
- Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs
- Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
- Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis
- Increasing Patient Engagement - The PAG Trend
- Gene Therapy and Bioprocessing Preferred over Chronic Therapies
- Companies Developing Gene Therapies
- International Collaboration - The Way Forward
- CNS Therapeutics to Gain Focus in the Orphan Drugs Market
- Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications
- Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications
- Treating Autism - The Next Big Thing?
- Sequencing Technology - The New Research Tool for Orphan Drugs
- Innovations in Biotechnology - A Boon for Orphan Drug Research
- Aging Gene Linked to Myeloma
- Antibody with Potential to Treat Multiple Myeloma
- Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus
- Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 3: World 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 6: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 9: World 16-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 12: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 15: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 18: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 21: World 16-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 24: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 27: World 16-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 28: World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 29: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 30: World 16-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 31: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 32: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 33: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
- Table 34: World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 35: USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: USA 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 38: USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: USA 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
CANADA
- Table 41: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: Canada 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 44: Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: Canada 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
JAPAN
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 47: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Japan 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 50: Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Japan 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
CHINA
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 53: China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: China 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 56: China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: China 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
EUROPE
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 59: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: Europe 16-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 62: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 65: Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
FRANCE
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 68: France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: France 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 71: France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: France 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
GERMANY
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 74: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: Germany 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 77: Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: Germany 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
ITALY
- Table 80: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Italy 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 83: Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Italy 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 86: UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: UK 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 89: UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: UK 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
REST OF WORLD
- Table 104: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Rest of World 16-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2014, 2023 & 2030
- Table 107: Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 109: Rest of World 16-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2014, 2023 & 2030
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Actelion Pharmaceuticals Ltd.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- AstraZeneca Plc.
- Bayer AG
- Biogen Inc.
- BioMarin Pharmaceutical Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Celgene Corp.
- CEL-SCI Corporation
- Concordia International Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genzyme Corp.
- Johnson & Johnson
- Merck & Co. Inc.
- Merck Serono SA
- Novartis AG
- Pfizer Inc.
- Recordati S.p.A.
- Sanofi SA
- Shire Plc.
- Vertex Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 261 |
| Published | April 2024 |
| Forecast Period | 2020 - 2027 |
| Estimated Market Value ( USD | $ 201.9 Billion |
| Forecasted Market Value ( USD | $ 545.4 Billion |
| Compound Annual Growth Rate | 15.3% |
| Regions Covered | Global |
